Literature DB >> 9455964

The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic.

F Wolfe1.   

Abstract

The prognosis of rheumatoid arthritis is best described separately for mortality, work disability, costs, functional disability, total joint arthroplasty, radiographic abnormality, and psychosocial factors. The most important determinants of prognoses are the severity and persistence of disease activity. Methods for disease activity assessment have been developed for use in clinical trials, but these are often not suitable for use in clinical practice because of time constraints, costs, and special training required. However, clinicians can measure disease activity relatively simply according to joint counts, acute-phase reactants, and patient self-report tests. Nomograms, based on percentile ranking of disease activity variables, are simple tools that can be used in the clinic to estimate disease activity and change in clinical status.

Entities:  

Mesh:

Year:  1997        PMID: 9455964     DOI: 10.1016/s0002-9343(97)90003-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement.

Authors:  F Wolfe; H K Choi
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 2.  Predictive factors of work disability in rheumatoid arthritis: a systematic literature review.

Authors:  E M de Croon; J K Sluiter; T F Nijssen; B A C Dijkmans; G J Lankhorst; M H W Frings-Dresen
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with rheumatoid arthritis symptoms.

Authors:  A González-Canga; K Ugai; M Suzuki; H Okuzawa; E Negishi; K Ueno
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

4.  A randomized trial of three psychosocial treatments for the symptoms of rheumatoid arthritis.

Authors:  Arthur J Barsky; David K Ahern; E John Orav; Yvonne Nestoriuc; Matthew H Liang; Ilana T Berman; Joshua R Kingsbury; Jennifer T Sy; Kathryn G Wilk
Journal:  Semin Arthritis Rheum       Date:  2010-12       Impact factor: 5.532

Review 5.  Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.

Authors:  P Emery; F C Breedveld; M Dougados; J R Kalden; M H Schiff; J S Smolen
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

Review 6.  Health economics: implications for novel antirheumatic therapies.

Authors:  A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

7.  Association of Rsa polymorphism of the estrogen receptor-β gene with rheumatoid arthritis.

Authors:  Hiromi Sato; Ayano Ito; Aránzazu González-Canga; Hiroko Okuzawa; Kanako Ugai; Masahiko Suzuki; Takao Namiki; Koichi Ueno
Journal:  Rheumatol Int       Date:  2011-04-27       Impact factor: 2.631

8.  Identification of autoantibodies against transthyretin for the screening and diagnosis of rheumatoid arthritis.

Authors:  Saurabh Sharma; Sreejoyee Ghosh; Lalit Kumar Singh; Ashish Sarkar; Rajesh Malhotra; Onkar Prasad Garg; Yogendra Singh; Radhey Shyam Sharma; Darshan Singh Bhakuni; Taposh Kumar Das; Sagarika Biswas
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

9.  Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis.

Authors:  Liseth Siemons; Peter M ten Klooster; Harald E Vonkeman; Mart A F J van de Laar; Cees A W Glas
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

10.  The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28.

Authors:  Masayo Sato; Sebastian Schneeweiss; Richard Scranton; Jeffrey N Katz; Michael E Weinblatt; Jerry Avorn; Gladys Ting; Nancy A Shadick; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2006-03-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.